Abstract 1677MO
Background
Individuals with cancer, particularly those who are receiving systemic anti-cancer treatments, have been postulated to be at increased risk of mortality from SARS-CoV-2 related coronavirus disease (COVID-19). This conjecture has considerable impact on the treatment of cancer patients and large, multi-centre data to support this assumption is lacking due to the contingencies of the pandemic.
Methods
The cancer community of the United Kingdom (UK) has launched the UK Coronavirus Cancer Monitoring Project (UKCCMP). The UKCCMP is the first COVID-19 clinical registry that enables near real-time reports to frontline doctors about the effect of COVID-19 on cancer patients.
Results
An analysis of the first 800 cancer patients with symptomatic COVID-19 disease entered into the UKCCMP registry has been performed. Approximately half of these patients have a mild COVID-19 disease course (52%). Mortality was observed in 226 patients (28%) and risk of death was significantly associated with advancing patient age, sex (M>F) and the presence of other co-morbidities. Approximately one third had received cytotoxic chemotherapy within 4 weeks prior to testing positive for COVID-19. After adjusting for age, sex and comorbidities, recent receipt of chemotherapy had no significant effect on mortality from COVID-19 disease, when compared to cancer patients who had not received recent chemotherapy. No significant effect on mortality was also observed for patients with recent immunotherapy, hormonal therapy, targeted therapy or radiotherapy use.
Conclusions
Mortality from COVID-19 in cancer patients appears to be principally driven by age, sex and co-morbidities. We are not able to identify evidence that cancer patients on cytotoxic chemotherapy or other anti-cancer treatment are at significantly increased risk of mortality from COVID-19 disease compared to those not on active treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Gary Middleton.
Funding
University of Birmingham.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1674MO - ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: Implications for SARS-CoV-2
Presenter: Riyue Bao
Session: Mini Oral - SARS-CoV-2 and cancer 2
Resources:
Abstract
Slides
Webcast
LBA81 - Keeping exhausted T-cells in check in COVID-19
Presenter: Pierre Van Mol
Session: Mini Oral - SARS-CoV-2 and cancer 2
Resources:
Abstract
Slides
Webcast
LBA82 - Influenza-like illness and SARS-Cov-2 in the multicenter, prospective, observational INVIDIa-2 study (INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: A transversal challenge): A FICOG study
Presenter: Melissa Bersanelli
Session: Mini Oral - SARS-CoV-2 and cancer 2
Resources:
Abstract
Slides
Webcast
1675MO - Screening of COVID-19 disease based on chest CT and PCR for cancer patients undergoing radiotherapy in a French coronavirus hotspot
Presenter: Roger Sun
Session: Mini Oral - SARS-CoV-2 and cancer 2
Resources:
Abstract
Slides
Webcast
1676MO - Prevalence and clinical impact of asymptomatic or mildly symptomatic SARSCoV-2 infection among actively treated cancer patients during COVID-19 pandemic in Italy
Presenter: Alberto Zambelli
Session: Mini Oral - SARS-CoV-2 and cancer 2
Resources:
Abstract
Slides
Webcast
LBA83 - Outcomes of the 2019 novel coronavirus in patients with or without a history of cancer: A multi-centre North London experience
Presenter: Nalinie Nalinie Joharatnam-Hogan
Session: Mini Oral - SARS-CoV-2 and cancer 2
Resources:
Abstract
Slides
Webcast
Open & welcome
Presenter: Lewis Au
Session: Mini Oral - SARS-CoV-2 and cancer 2
Resources:
Slides
Webcast
Invited Discussant 1674MO, LBA81 and LBA82
Presenter: Lewis Au
Session: Mini Oral - SARS-CoV-2 and cancer 2
Resources:
Webcast
Invited Discussant 1675MO, 1676MO, LBA83 and 1677MO
Presenter: Donna Rivera
Session: Mini Oral - SARS-CoV-2 and cancer 2
Resources:
Slides
Webcast